59
Participants
Start Date
October 31, 2015
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
leukapheresis
Plerixafor
Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
carmustine, etoposide, cytarabine, melphalan
Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Northwell Health (Data collection only), Manhasset
Memorial Sloan Kettering Nassau (Consent and Follow up Only), Uniondale
Memorial Sloan Kettering Commack (Consent and Follow-up Only), Commack
University of Rochester Medical Center, Rochester
Tennessee Oncology, Nashville
Medical College of Wisconsin, Milwaukee
Texas Transplant Institute, San Antonio
University of Nebraska Medical Center, Omaha
Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only), Basking Ridge
Columbia University, New York
Memorial Sloan Kettering Monmouth (Consent and Follow up Only), Middletown
Memorial Sloan Kettering Bergen (Consent and Follow Up Only), Montvale
Collaborators (2)
Columbia University
OTHER
Endeavor Health
OTHER
University of Rochester
OTHER
Medical College of Wisconsin
OTHER
University of Nebraska
OTHER
Sanofi
INDUSTRY
University Hospitals Seidman Cancer Center
OTHER
Memorial Sloan Kettering Cancer Center
OTHER